Despite advances in medical therapies, pulmonary arterial hypertension (PAH) continues to cause significant morbidity and mortality. Although the right ventricle (RV) can adapt to an increase in afterload, progression of the pulmonary vasculopathy that characterizes PAH causes many patients to develop progressive right ventricular failure. Furthermore, acute right ventricular decompensation may develop from disorders that lead to either an acute increase in cardiac demand, such as sepsis, or to an increase in ventricular afterload, including interruptions in medical therapy, arrhythmia, or pulmonary embolism. The poor reserve of the right ventricle, RV ischemia, and adverse right ventricular influence on left ventricular filling may lead to a global reduction in oxygen delivery and multiorgan failure. There is a paucity of data to guide clinicians caring for acute right heart failure in PAH. Treatment recommendations are frequently based on animal models of acute right heart failure or case series in humans with other causes of pulmonary hypertension. Successful treatment often requires that invasive hemodynamics be used to monitor the effect of strategies that are based primarily on biological plausibility. Herein we have developed an approach based on the current understanding of RV failure in PAH and have attempted to develop a treatment paradigm based on physiological principles and available evidence.

Keywords: pulmonary hypertension; right ventricular failure; intensive care; extracorporeal life support

Right ventricular (RV) failure is the most common cause of death in patients with pulmonary hypertension, and RV function is the major determinant of morbidity and mortality in this patient population. There is, however, no universally accepted definition of RV failure. Clinically, RV failure is characterized by a reduced cardiac output (i.e., cardiac index < 2.5 L/min/m²) and an elevation in RV filling pressure (i.e., right atrial pressure > 8 mm Hg).

Right ventricular failure is a common complication of pulmonary hypertension (PH). RV failure can also result from other diseases such as myocarditis, cardiomyopathy, or myocardial infarction, but these conditions are not covered in the present overview. Although any form of PH can result in RV dysfunction, the full picture of RV failure with low cardiac output and elevated RV filling pressures is typically seen in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), that is, groups 1 and 4 according to the current classification (Table 1) (2, 3). Patients with PH due to left heart disease (Table 1, group 2) or due to lung disease and/or hypoxia (Table 1, group 3) may also present with clinical signs and symptoms of RV failure, especially with fluid retention associated with RV diastolic dysfunction and elevated right-sided filling pressures. Low cardiac output RV failure, however, is less common in these patient populations. On occasion, patients may present with clinical signs of RV failure in a state of markedly elevated rather than reduced cardiac output. This so-called high-output failure is typically seen in patients with large arteriovenous malformations (e.g., in patients with hereditary hemorrhagic telangiectasia) (4), or in patients with chronic hemolytic anemia (e.g., sickle cell disease) (5), and is not addressed further in this review.

In the past it was not unusual to see patients being admitted to the intensive care unit (ICU) with RV failure due to undiagnosed and untreated PAH. Fortunately, with increased awareness of the condition, this scenario has become increasingly rare. Today, the majority of patients with PH and RV failure admitted to the ICU have exhausted their medical treatment options, which renders their management particularly challenging and, at times, frustrating. Patients with overt RV failure have never been included in randomized, controlled clinical trials and few articles have specifically addressed this patient population. Contemporary guidelines make no specific recommendations regarding the ICU management of patients with RV failure (6–9). To the best of our knowledge, only a few authoritative review articles on this subject have been published (10–13) and an update seems timely given the advances in this area. A systematic review of the treatment of patients with pulmonary hypertension was completed by Price and coworkers (11). As emphasized in that report, many of the treatments have not been systematically evaluated and most of the recommendations relate to biological plausibility and extrapolation from acute animal models of PH.

In this article we review the ICU management of patients with PH and RV failure. We are not going to address acute pulmonary embolism and postoperative right heart failure after cardiac surgery, and will not cover the specific considerations regarding pediatric patients with pulmonary vascular disease. Our recommendations are based on physiological principles, published reports as well as personal experience.

PATHOPHYSIOLOGY OF RIGHT VENTRICULAR FAILURE

The RV is embryologically, morphologically, and functionally distinct from the left ventricle (LV) (14–17). After birth it assumes the adult phenotype of a relatively thin-walled, crescent-shaped structure that is adapted to eject into the pulmonary circulation; a circuit characterized by low resistance, high compliance, and low impedance (15). The RV and LV are interrelated by the shared interventricular septum. The relatedness is also conferred by the surrounding pericardium, which ensures a consistent beat-to-beat intracardiac volume (18, 19). RV–LV interaction, under
normal conditions, allows the ejection of the RV to be augmented by left ventricular ejection (20, 21). Although highly efficient, the naïve RV poorly adapts to sudden increases in afterload (Figure 1). An increase in RV end-diastolic volumes likely initially improves cardiac output by the Frank-Starling mechanism; however, a severe and sudden increase in right ventricular afterload may overwhelm the contractile capability of the RV and lead to hemodynamic collapse (16, 22–26). Ventriculoarterial coupling is a major determinant of RV function as it relates RV end-systolic elastance (a load-independent measure of contractility) relative to pulmonary arterial elastance (difference in end-systolic and end-diastolic RV pressure relative to stroke volume) (27–30). Normal coupling represents a point at which there is adequate flow output at the lowest energy cost. Patients with pulmonary hypertension may have a reduction in RV elastance relative to PA elastance, and the development of RV failure may be defined as a progressive disruption of the normal ventriculoarterial coupling (27). When RV afterload increases more gradually, RV adaptation occurs (31, 32). In an animal model of acute RV afterload, RV adaptation was observed within 96 hours (33). This adaptive myocardial hypertrophy is thought to reduce wall stress and maintain an adequate stroke volume (32, 34–37). However, in the face of a progressive or sudden worsening in RV afterload these compensatory mechanisms are overwhelmed.

A reduction in oxygen delivery in PAH may be mediated through two mechanisms. First, it may result from a decrease in LV filling resulting from reduction in pulmonary blood flow. Second, RV enlargement may lead to reduced LV filling because of direct RV impingement on LV filling mediated by septal wall motion displacement by a pressure- and volume-overloaded RV (15, 20, 38–41). In both acute and chronic pulmonary hypertension, this adverse effect on left ventricular filling has been shown to be augmented by an increase in pericardial pressure caused by an enlarged RV (42). In this instance an elevation in right atrial pressure (a reasonable surrogate for pericardial pressure) should raise the possibility that changes in pulmonary capillary wedge pressure (PCWP) will be an unreliable estimate of LV preload. As such it becomes important for the clinician to consider transmural pressure (left ventricular end-diastolic pressure – pericardial pressure) as a more accurate reflection of LV filling. Practically, transmural pressure may be estimated as PCWP – right atrial (RA) pressure (42). It is important to recognize that in this adverse situation, volume loading may paradoxically lead to a reduction in left ventricular filling (43). Conversely, a reduction in right ventricular volume (mediated through diuresis) may improve left ventricular filling and cardiac output through a reduction in pericardial pressure and reduced influence of septal displacement. In this volume-overloaded state both RV filling and LV filling are also highly susceptible to the deleterious effects of tachycardia and tachyarrhythmia, which may further reduce LV filling and stroke volume (39). Last, prolongation of RV contraction causes RV contraction to continue beyond LV contraction, with resultant RV systolic encroachment on LV filling (44). This adverse ventricular interaction may be further enhanced through prolongation of RV contraction. This prolongation causes RV contraction to continue beyond LV contraction, resulting in RV systolic encroachment on LV filling (44). RV coronary blood flow also decreases as RV wall tension increases (45). Acute increases in wall tension may lead to RV ischemia and hemodynamic collapse. More sustained regional ischemia may lead to focal fibrosis, particularly at the insertion sites of the RV free wall on the interventricular septum.

**TABLE 1. UPDATED CLINICAL CLASSIFICATION OF PULMONARY HYPERTENSION**

<table>
<thead>
<tr>
<th>1. Pulmonary arterial hypertension (PAH)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1. Idiopathic PAH</td>
<td></td>
</tr>
<tr>
<td>1.2. Heritable</td>
<td></td>
</tr>
<tr>
<td>1.2.1. BMPR2</td>
<td></td>
</tr>
<tr>
<td>1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)</td>
<td></td>
</tr>
<tr>
<td>1.2.3. Unknown</td>
<td></td>
</tr>
<tr>
<td>1.3. Drugs and toxins induced</td>
<td></td>
</tr>
<tr>
<td>1.4. Associated with</td>
<td></td>
</tr>
<tr>
<td>1.4.1. Connective tissue diseases</td>
<td></td>
</tr>
<tr>
<td>1.4.2. HIV infection</td>
<td></td>
</tr>
<tr>
<td>1.4.3. Portal hypertension</td>
<td></td>
</tr>
<tr>
<td>1.4.4. Congenital heart diseases</td>
<td></td>
</tr>
<tr>
<td>1.4.5. Schistosomiasis</td>
<td></td>
</tr>
<tr>
<td>1.4.6. Chronic hemolytic anemia</td>
<td></td>
</tr>
<tr>
<td>1.5. Persistent pulmonary hypertension of the newborn</td>
<td></td>
</tr>
</tbody>
</table>

**1. Pulmonary artery hypertension (PAH)**

1.1. Idiopathic PAH

1.2. Heritable

1.2.1. BMPR2

1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)

1.2.3. Unknown

1.3. Drugs and toxins induced

1.4. Associated with

1.4.1. Connective tissue diseases

1.4.2. HIV infection

1.4.3. Portal hypertension

1.4.4. Congenital heart diseases

1.4.5. Schistosomiasis

1.4.6. Chronic hemolytic anemia

1.5. Persistent pulmonary hypertension of the newborn

**Definition of abbreviations:** ALK1 = activin receptor-like kinase-1 gene; BMPR2 = bone morphogenetic receptor-2 gene; PH = pulmonary hypertension. From Reference 2.

**FACTORS TRIGGERING RIGHT VENTRICULAR FAILURE IN PATIENTS WITH PULMONARY HYPERTENSION**

Progressive obliteration of the pulmonary vascular bed inevitably results in RV failure once the adaptive mechanisms of the RV are exhausted (46). Contemporary treatment with endothelin receptor antagonists, phosphodiesterase (PDE)-5 inhibitors, and prostacyclin derivates can sometimes slow disease progression in patients with PAH; however, mortality remains high in this patient population (47–49). Hence, RV failure is frequently encountered as a manifestation of disease progression despite targeted therapy. In many instances, however, triggering factors causing or aggravating RV failure can be identified, especially infections, anemia, trauma, surgery, pregnancy, nonadherence with therapy, pulmonary embolism, and arrhythmias (50). Identifying and treating these conditions is critical. A French series of 46 patients with PAH admitted to the ICU for RV failure (50) found a triggering factor in 19 (41%) patients, including unplanned withdrawal of PAH-targeted therapy (n = 3) or diuretics (n = 1), pregnancy (n = 1), sepsis (n = 7), pneumonia (n = 5), and arrhythmia (n = 3). Documented infection at any time during the ICU stay was the strongest predictor of death, occurring in 74% of the nonsurvivors compared with 22% of the survivors (P = 0.0005), and underscoring the need for aggressive management of infectious complications in these patients. It is likely that the bowel is a major source of bacteremia and endotoxinemia in patients with pulmonary hypertension, as the combination of low cardiac output and elevated venous pressures may result in a loss of the intestinal barrier function (51, 52).
Arrhythmias are another treatable cause of RV failure in patients with PH. Whereas ventricular arrhythmias, especially ventricular flutter and ventricular fibrillation, have rarely been reported in these patients (53), atrial tachyarrhythmia (most importantly atrial tachycardia), atrial flutter, and atrial fibrillation are increasingly encountered (54). As augmented atrial contractility is an important compensatory mechanism in patients with a noncompliant RV (55), the loss of atrial contractions may have deleterious consequences for RV function. In patients with advanced PAH, new-onset atrial flutter or atrial fibrillation almost invariably results in RV failure. The management of supraventricular tachyarrhythmia in patients with PH has never been evaluated in clinical trials, but clinical experience indicates that the strategies derived from patients with left heart disease may not be fully applicable to patients with PH. Most importantly, rate control alone does not appear to be sufficient and restoration of sinus rhythm seems to be critical (54). Antiarrhythmics or electrical cardioversion may be required when patients are acutely unstable or have a new onset of arrhythmia. Atrial fibrillation is typically more difficult to treat than flutter. In general, β-blocking agents and calcium channel blockers should be avoided as they may further impair RV function. Digitalis glycosides are of limited value but may be used for rate control. In our centers, electrical cardioversion of new-onset atrial fibrillation is almost always attempted, usually after pretreatment with amiodarone, which is then continued indefinitely to prevent relapse. The treatment of choice for refractory atrial flutter or atrial tachycardias is radiofrequency ablation.

**MONITORING ON THE ICU**

Evaluation of cardiac function as well as end-organ function is critical in managing patients with RV failure (Table 2). Measurements of renal, liver, and neurological function will provide some information about the adequacy of cardiac function and tissue perfusion. Echocardiography may be useful in the acute setting; however, the quantification of RV function by this method is thwarted by the nonsymmetrical shape of the RV, making it difficult to reproducibly assess RV contractility or volume. Other echocardiographic measures including tricuspid annular plane excursion and the Tei index, have been shown to be potentially valuable measures in monitoring patients with PAH (56–58). The degree of RV influence on LV size can be quantified by the deformity index, essentially a measure of the degree of septal bowing (59). However, the utility of these echocardiographic measures in the acute care setting has not been evaluated. Other methods including tissue Doppler and three-dimensional echocardiography remain potentially valuable methods for assessing RV function in the clinical setting, but
are not applicable for making repeated measures in hemody-
namically unstable patients (60–62).

Studies have cast doubts on the utility of invasive measure-
ment of cardiac function in critically ill patients with vasodilatory
or cardiogenic shock (63, 64). However, for patients admitted to
the ICU with severe PH and RV failure we advocate for the
placement of invasive methods allowing for the measurement of
RA pressure, left atrial pressure, cardiac output, and mixed-
venous oxygen saturation (ScvO₂). Measurement of pulmonary
vascular resistance (PVR) is a composite index of pulmonary
pressure and cardiac output. However, PVR may not accurately
reflect right ventricular afterload. Unfortunately, more sophis-
ticated measures of RV afterload are physiologically more rel-
vent but generally not clinically feasible (28). Ultimately the
success (or not) of a treatment strategy should be guided by the
adequacy of tissue oxygen, which is partly reflected by measure-
ments such as ScvO₂ or central venous oxygen saturations
(ScvO₂). Plasma lactate levels should be monitored closely, as
elevated and/or increasing levels may signal progressive RV
failure. The use of brain natriuretic peptide measurements to
guide care may be of value to document trends in the adequacy
of cardiac function over time, but may not provide sufficient
real-time information to inform decisions about treatment in
an unstable patient.

MANAGEMENT OF RV FAILURE IN PATIENTS WITH
PULMONARY ARTERIAL HYPERTENSION

The management of RV failure in patients with PAH is complex
and requires expertise. If such patients are admitted to nonspe-
cialized centers a PH referral center should be contacted as soon
as possible to discuss treatment options and possible interhosp-
ter transfer.

RV failure eventually results in multiorgan dysfunction. Red-
cuced cardiac function can result in decreased bowel perfusion,
loss of the intestinal barrier function, and bacterial translocation,
a complication that has been implicated as a common cause of
death in these patients (51, 54). Reduced hepatic perfusion can
impair liver function or may even result in liver failure. Renal
failure is another disastrous complication of RV failure.

The initial focus of care should center on addressing any pot-
tial reversible cause of acute RV decompensation (see above)
and development of a strategy to improve RV function. The
latter may be achieved through modifying RV preload, contrac-
tility, and afterload. Consideration must also be given to main-
taining coronary perfusion and avoiding tachycardia (Table 2
and Figure 1). Meticulous fluid management, reducing venous
filling pressures, and normalizing cardiac output are the main
tools to recompensate these patients. The importance of ap-
propriate hemodynamic monitoring has been outlined previously
and close monitoring of blood pressure, urine production, RA
pressure, and ScvO₂ or SvO₂ are crucial to guide treatment strat-
egies in these patients.

Fluid Management

Fluid management of these patients is often difficult, as both
hypovolemia and hypervolemia can have detrimental effects
on blood pressure, organ perfusion, and cardiac function. Earlier
studies have suggested that fluid loading may improve hemody-
namics in patients with acute pulmonary embolism (65), but
unmonitored fluid challenge may further impair RV function
(see above). In most, but not all, cases, RV failure is associated
with fluid overload and a negative fluid balance is the key to
successful therapy. However, fluid removal may reduce the al-
ready low cardiac output and may thereby further impair end-
organ function.

The ICU management of patients with predominantly dia-
static dysfunction of the RV, elevated filling pressures, and fluid
retention in the presence of normal or near-normal cardiac out-
put and normal blood pressure is straightforward, as these
patients can usually be managed with diuretic therapy.

Maintaining Cardiac Output and Systemic Blood Pressure

Systolic RV failure with low cardiac output and hypotension is
more difficult to treat and may require catecholamines or vaso-
pressin to stabilize blood pressure and cardiac output. The β₁-
agonist dobutamine augments myocardial contractility and
reduces right and left ventricular afterload, which makes it the
preferred catecholamine for patients with RV failure (12, 50).
However, the use of β-adrenergic agents may lead to tachycar-
dia. Patients with pulmonary hypertension may be particularly
vulnerable to the adverse effects of tachycardia on diastolic
filling time. Consequently, agents that do not have chronotropic
properties, such as PDE-3 inhibitors, may be preferable in some
patients. PDE-3 inhibitors may have direct inotropic effects by
increasing levels of endogenous cAMP and indirectly augment
cardiac function by reducing afterload. Although these agents
received a high recommendation in the systematic review by
Price and colleagues, most of the referenced studies were com-
pleted in patients with PH secondary to left ventricular failure,
postventricular assist, or cardiac transplantation (11). Despite

TABLE 2. RECOMMENDED MONITORING OF THE CRITICALLY ILL PATIENT WITH SEVERE PULMONARY ARTERIAL HYPERTENSION

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Modality</th>
<th>Treatment Goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal function</td>
<td>Urinary catheter</td>
<td>Maintain kidney function and diuresis. In general a net</td>
</tr>
<tr>
<td></td>
<td>Serum creatinine</td>
<td>negative fluid balance is required</td>
</tr>
<tr>
<td>Liver function</td>
<td>AST, ALT, bilirubin</td>
<td>Reduce hepatic congestion</td>
</tr>
<tr>
<td>Cardiac function</td>
<td>Central venous line (central venous pressure, ScvO₂)</td>
<td>Improvement in cardiac function demonstrated by an increase in cardiac output with improvement (reduction) in right atrial pressures</td>
</tr>
<tr>
<td></td>
<td>Pulmonary arterial catheter (RA pressure, cardiac index, PAPm, PVR, SvO₂)</td>
<td>ScvO₂ &gt; 70%</td>
</tr>
<tr>
<td></td>
<td>Echocardiography</td>
<td>ScvO₂ &gt; 65%</td>
</tr>
<tr>
<td>Tissue perfusion/oxygenation</td>
<td>Lactate</td>
<td>Improve LV filling</td>
</tr>
<tr>
<td>Neurohormonal markers</td>
<td>Brain natriuretic peptides (BNP or NT-proBNP)</td>
<td>&lt;2.0 mmol/L</td>
</tr>
<tr>
<td>Myocardial perfusion</td>
<td>Systemic blood pressure (noninvasive or invasive)</td>
<td>Reduction in BNP levels</td>
</tr>
<tr>
<td></td>
<td>ECG</td>
<td>Ensure adequate systemic diastolic pressure (&gt;60 mm Hg)</td>
</tr>
<tr>
<td></td>
<td>Troponin</td>
<td>Avoid/treat tachycardia/tachyarrhythmia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Optimize myocardial perfusion (negative troponin)</td>
</tr>
</tbody>
</table>

Definition of abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; BNP = brain natriuretic peptide; ECG = electrocardiogram; LV = left ventricle; NT-proBNP = N-terminal fragment of brain natriuretic peptide; PAPm = mean pulmonary arterial pressure; PVR = pulmonary vascular resistance; RA = right atrial; ScvO₂ = central venous oxygen saturation; SvO₂ = mixed venous oxygen saturation.
potential advantages of these agents, systemic vasodilatation may limit the use or require concomitant administration of a systemic vasoconstrictor such as norepinephrine. A few reports suggest that inhaled milrinone might be useful in RV failure, as this mode of application allows preferential pulmonary vasodilatation without the risk of systemic hypotension (66, 67).

Profound or persistent hypotension, especially in patients with low systemic vascular resistance due to infection, may require additional therapy with norepinephrine, a vasoconstrictor stimulating α1- and β1-adrenergic receptors. Adequate systemic blood pressure is required to ensure adequate coronary perfusion in these patients, which is a prerequisite to maintain cardiac function (68). Furthermore, there is a suggestion that an increase in LV afterload may improve the adverse conformational shape that the dilated RV imposes on an underfilled LV. The downside of higher doses of norepinephrine is its potential detrimental effect on pulmonary vascular resistance (69). Vasopressin may be an alternative to norepinephrine as this drug has systemic vasoconstrictive but pulmonary vasodilatory properties, but there are few clinical data supporting its use in patients with pulmonary hypertension (70–72). Lевosimendан, a calcium-sensitizing agent with positive inotropic and vasodilatory effects, holds promise for patients with PH and RV failure (73, 74), but it has not yet been thoroughly investigated in these patients (75–78).

Oxygen and Ventilator Support

Maintaining sufficient oxygen supply is self-evident. This includes supplemental oxygen to keep peripheral oxygen saturation above 90% and the correction of anemia, if present. The ideal hemoglobin level of patients with RV failure due to PH has never been studied, but given the likelihood that anemia (and even isolated iron deficiency) may worsen RV function, we suggest that hemoglobin levels greater than 10 g/dl be maintained (79).

Every attempt should be made to avoid endotracheal intubation of patients with RV failure (80). Intubation of these patients is often problematic owing to effects of sedatives on cardiac function and nonselective vasodilatation leading to systemic hypertension and hemodynamic collapse.

Continuous positive airway pressure or noninvasive ventilation may be considered, but opioids or sedatives should be administered with great care to avoid drops in blood pressure. If intubation and mechanical ventilation are unavoidable, hypotension and loss of RV contractility must be prevented and the administration of catecholamines before anesthesia should be considered. Despite the lack of controlled clinical trials, etomidate is the preferred drug for induction of general anesthesia as it has little effect on cardiac contractility and vascular tone (81, 82). Maintenance of anesthesia is usually achieved with low-dose opioids or ketamine together with benzodiazepines or propofol. Airway pressures should be kept to a minimum while at the same time hypercapnia must be prevented because of its deleterious effects on pulmonary hemodynamics (12, 83, 84). Attempts at cardiopulmonary resuscitation remain largely unsuccessful in patients with PAH and RV failure (53).

Percutaneous Interventions

The presence of large pericardial effusions is associated with a poor prognosis in patients with pulmonary arterial hypertension, but the presence of tamponade may be difficult to determine on the basis of typical echocardiographic criteria. In general, draining pericardial effusions should be avoided. Although anecdotal case reports suggest that opening of the pericardium may improve cardiac function (85), two small series reported 50% mortality in patients who had their effusion drained (86, 87).

Balloon atrioseptostomy (BAS) is used in some pulmonary hypertension centers as treatment of severe pulmonary hypertension. BAS decompresses the enlarged RV and improves LV filling as well as cardiac output. Despite oxygen desaturation, the net effect is usually an increase in systemic oxygen transport (88). In experienced centers BAS is considered a safe procedure as long as it is performed in hemodynamically stable patients (89). However, BAS is not recommended as an emergency procedure for patients with RV failure, as the risk of fatal complications is high in patients with markedly elevated RV-filling pressures (RA pressure > 20 mm Hg) and/or low oxygen saturations (not recommended for patients with O2 saturation at rest < 80% on room air) (6).

Reducing RV Afterload

One of the most important interventions to reverse RV failure is to reduce RV afterload through the use of pulmonary vasodilators or PAH-targeted therapies. The importance of reducing RV afterload is emphasized by the rapidity with which RV function is restored after pulmonary endarterectomy and lung transplantation (90–95). The use of PAH-targeted therapies depends primarily on previous treatment. In therapy-naive patients with PAH (or other severe forms of PH) and RV failure, inhaled prostacyclin derivatives (epoprostenol, treprostinil, iloprost) are the initial treatment of choice, although care must be taken to avoid systemic hypotension. It needs to be emphasized that intravenous epoprostenol remains the only PAH therapy for which improved survival has been demonstrated in a randomized, controlled clinical trial. Once these patients have been stabilized, oral therapies with endothelin receptor antagonists and PDE-5 inhibitors may be added with or without later withdrawal of the prostanoïd. Intravenous prostacyclin derivatives are also the preferred therapy for patients who have been pre-treated with nonparenteral drugs, although the clinical response is sometimes less impressive than in treatment-naive patients. Inhaled vasodilators such as nitric oxide or iloprost might be used as supplementary therapy (94–96), especially in patients who do not tolerate parenteral prostanoïds because of systemic hypotension. Inhaled NO is frequently used in intubated patients, for instance, in patients with PH and RV failure after cardiac surgery (97–99). Oral drugs, especially endothelin receptor antagonists and phosphodiesterase-5 inhibitors, have not been investigated in the setting of RV failure and are usually not recommended as initial treatment. An intravenous formulation of the PDE-5 inhibitor sildenafil has become available that might be useful in the ICU management of RV failure, but it also needs to be further evaluated, especially regarding the risks of systemic hypotension (100). Nonspecific vasodilators such as calcium channel blockers may cause profound systemic hypotension and should therefore be avoided in patients with RV failure.

For patients in whom all conventional treatment options including intravenous prostacyclin derivatives have been exhausted, ICU treatment will have to rely primarily on the general measures outlined previously, focusing on careful fluid management and a judicious choice of catecholamines. In these dire cases, the outcome will depend mostly on whether triggering factors can be identified and corrected, and whether transplantation is a potential option (see below).

SPECIAL CONSIDERATIONS FOR OTHER FORMS OF PULMONARY HYPERTENSION

PAH Subpopulations

PAH, the prototype of PH, is generally treated according to the above-mentioned considerations, and there are usually no
further specific treatment options. This is also true for most of the cases in which PAH is associated with connective tissue disease. One important exception are patients with systemic lupus erythematosus (SLE) and PAH. In these patients, flare-ups in lupus activity are often accompanied by worsening of PAH. Therefore aggressive immunosuppression in addition to PAH therapy should be considered if these patients present with evidence of clinically or serologically active SLE and RV failure. Although evidence to support this practice is limited to case reports, pulse steroids and either azathioprine or cyclophosphamide are commonly used in these patients (101).

**PH Associated with Left Heart Disease**

Patients with systolic left ventricular dysfunction may have an increase in RV afterload due to a passive increase in pulmonary pressure resulting from an increase in left ventricular end-diastolic pressure and, variably, an active component relating to an increase in transpulmonary gradient (mean pulmonary arterial pressure – PCWP). In these patients, treatment should focus on strategies to improve left ventricular function through manipulating preload, contractility, and afterload. However, even after successful treatment and a reduction in left atrial/ left ventricular end-diastolic pressure, the transpulmonary gradient may remain elevated. This is particularly relevant for patients who are being considered for heart transplantation or left ventricular assist device placement, where the presence of a refractory elevation in PVR and RV dysfunction may disqualify them for transplantation or lead to a requirement for mechanical RV support. Although initial reports have suggested that pulmonary vasodilators may have led to harm in patients with LV dysfunction and PH, more recent studies in patients with a persistently elevated transpulmonary gradient despite medically optimized LV function or mechanical support have shown benefit from pulmonary vasodilators such as sildenafil (102). However, further studies are needed to assess whether this leads to improved outcome. Aside from these unique settings, pulmonary vasodilators currently play no role in the ICU management of patients with left heart failure, even if they suffer from pulmonary hypertension.

**Although pulmonary hypertension may complicate acute respiratory distress syndrome, it is typically not hemodynamically relevant to patients without preexisting PAH and usually does not require specific treatment. In patients with PH in the setting of obstructive, fibrotic, or hypventilation syndromes, treatment generally centers around correcting hypoxemia and hypercapnia. Patients presenting with hypcapnic respiratory failure and PH with signs of RV failure often recover rapidly on standard therapy including noninvasive ventilation. No pulmonary vasodilator therapy has been systematically evaluated in these patients. Indeed, the use of pulmonary vasodilators in the treatment of these conditions is controversial as they may further impair gas exchange.**

**Chronic Thromboembolic Pulmonary Hypertension**

Patients with CTEPH presenting with RV failure are generally treated according to the same principles outlined previously. One important consideration is the likelihood of a new episode of acute pulmonary embolism. Even small pulmonary emboli may cause hemodynamic deterioration in patients with pre-existing pulmonary hypertension, and it is often impossible to distinguish old from new thrombotic material on a computed tomographic scan. Old thrombotic material is fully organized and therefore not amenable to medical therapy, but fibrinolytic therapy may be considered if there is a high likelihood of an acute-on-chronic event. If patients with CTEPH cannot be stabilized by medical therapy, emergency pulmonary endarterectomy should be considered (103). Of note, this procedure is different from pulmonary embolectomy and requires surgical expertise that is available only in specialized centers.

**Pulmonary Venoocclusive Disease**

Pulmonary venoocclusive disease represents a significant challenge. This diagnosis should be suspected in a patient who satisfies the diagnostic criteria for idiopathic pulmonary arterial hypertension but who has computed tomographic evidence of patchy ground-glass opacities, septal lines, pleural effusions, and/or mediastinal adenopathy (104, 105). It is important to emphasize that the pulmonary capillary wedge pressure is often normal in these patients, as disease relates to an increase in pulmonary venous vascular resistance and not alterations in left atrial compliance. Therefore in a zero-flow state (after balloon occlusion) the effect of the high venous resistance to flow is not measured. These patients may also have significant hypoxemia from the resultant interstitial and alveolar edema. It is important to recognize that classical pulmonary vasodilators may improve cardiac output but worsen lung edema (106, 107). Apart from attempts at aggressive diuresis there is no temporizing therapy available for these patients. Even though some patients with pulmonary venoocclusive disease may show a transient response to pulmonary vasodilators, the only definitive treatment for these patients is lung transplantation.

**LUNG TRANSPLANTATION, BRIDGING, AND EXTRACORPOREAL LIFE SUPPORT**

Despite advances in medical therapy, lung or heart–lung transplantation (H/LTx) remains an important treatment option for patients with progressive PH, especially for patients with refractory RV failure (108). A review of patient selection and of indications and contraindications for H/LTx is beyond the scope of this article and has been addressed elsewhere (109). For patients requiring ICU care for PAH and RV failure, several important decisions regarding transplantation need to be made: (1) Is the patient suffering from end-stage RV failure not responding to optimized medical therapy? (2) Provided the answer to the first question is yes, is the patient a potential candidate for H/LTx, and is it possible to realize transplantation in a reasonable time frame (what is reasonable will depend on patient factors as well as local organ allocation rules and organ availability)? (3) If the answer to the second item is also yes, may the patient benefit from extracorporeal life support (ECLS)?

Once a decision to proceed with H/LTx has been made, the treatment strategies described previously become bridging strategies. Maintaining cardiac output and preventing secondary organ failure are the most important objectives, but the means to establish these objectives in patients with end-stage disease are limited. The use of ECLS has become the preferred bridging strategy for patients with RV failure in some high-volume transplantation centers (110–113). With appropriate ECLS, the RV is immediately unloaded; PAH therapy and catecholamines are usually no longer required, and the perfusion of other organs, especially bowel, liver, and kidneys, dramatically improves. ECLS should therefore be considered in patients with refractory hypotension and/or signs of progressive secondary organ dysfunction, at least when prompt transplantation is a realistic option. Several advances have led to renewed interest in, and hitherto unseen success of, ECLS as a bridge to transplantation: the development of improved devices with centrifugal blood pumps and low-resistance, heparin-coated biocompatible oxygenators.
and the application of ECLS devices in awake, nonintubated patients as well as the use of pumpless devices inserted between the pulmonary artery and the left atrium. However, long-term use of ECLS requires intense anticoagulation and bleeding problems remain a main source of complication in patients treated with such devices.

**Venoarterial ECMO in Nonintubated Patients As a Bridge to Transplantation**

Venoarterial extracorporeal membrane oxygenation (v/a ECMO) has been attempted as a bridge to transplantation in intubated patients with RV failure. These patients were exposed not only to the risks associated with ECMO but also to the risks and complications of prolonged sedation and mechanical ventilation, especially pneumonia and septicemia. Not surprisingly, the outcomes associated with this strategy were sobering.

The group from Hannover Medical School (Hannover, Germany) reported on a series of five patients with RV failure who were treated by v/a ECMO while awake and breathing spontaneously (112). All patients had severe cardiopulmonary failure and were deemed moribund, but rapid improvement occurred after ECMO implantation, including an almost immediate recovery of renal function in those patients who presented with kidney failure. Four patients were successfully bridged to transplantation after 18–35 days on ECMO support and three of them were...
successfully transplanted and survived for more than 1 year. This small case series demonstrated the feasibility of v/a ECMO in patients with terminal RV failure, offering a salvage strategy for these patients if other treatments fail. The main disadvantages of v/a ECMO include the risk of bleeding complications related to anticoagulation and the fact that the patients cannot be fully mobilized with the device in place (Figure 2).

Pumpless Lung Assist Devices Inserted into the Pulmonary Circulation
An alternative bridging strategy is the use of a pumpless device inserted between the pulmonary arteries and the left atrium (PA–LA). The first report on the successful application of the PA–LA approach was published by groups from Germany and Canada (113, 114). They used an interventional lung assist device designed by Novalung (Hechingen, Germany), a low-resistance membrane oxygenator, originally developed for insertion between a femoral artery and a femoral vein to allow extracorporeal CO2 removal (110, 111, 115) (Figure 3). In patients with PAH, the device was connected between the main pulmonary artery and the left atrium. The patient’s RV drives blood flow through the device, thus obviating the need for a pump.

The insertion of this device requires general anesthesia, intubation, mechanical ventilation, and sternotomy. The centers using this technique so far prefer to place the patients on v/a ECMO before the procedure to avoid hemodynamic instability after intubation. The ECMO cannulas are later removed once blood flow through the Novalung device has been established. As with v/a ECMO, this approach results in immediate stabilization of hemodynamics and gas exchange. Most of the patients can be extubated after the procedure. The insertion of the PA–LA device is more elaborate than implanting a v/a ECMO. However, the PA–LA approach requires no blood pump and the patients can be fully mobilized. In addition, this technique leads to reconditioning of the deprived and stiff left ventricle, which may help to avoid complications after the transplantation.

ETHICAL CONSIDERATIONS AND END-OF-LIFE CARE
Ideally, questions related to prognosis, the possibility of transplantation, and patient’s wishes concerning end-of-life care should be discussed in a calm atmosphere between the patient, his family, and his caregivers during the course of the disease. The ICU is not the best setting to address these complex questions for the first time, especially as decisions often need to be made rapidly. In patients with end-stage PH in whom all available treatment options have been exhausted, limitations on advanced treatments should be considered and discussed with the patient and/or his relatives, when appropriate. This may imply the decision not to admit a patient to the ICU if the prognosis is poor. In such cases, providing comfort and symptom relief may become the main objectives, as in other patients approaching the end of their lives.

Novel technical developments such as ECLS may create hope but at the same time new ethical dilemmas. So far predominantly used as a bridge to transplantation, ECLS may also be considered a bridge to recovery in patients with treatable triggers of RV failure. Without the perspective of transplantation, however, ECLS strategies will frequently fail, which may result in complex decisions about if and when to conclude this treatment. Similar problems will arise when ECLS devices are being used in pregnant patients (116). Although this strategy may stabilize the mother for weeks or even months, thus allowing maturation of the fetus and successful delivery, there is a high likelihood that it will be impossible to wean the mother from the device, causing immense psychological problems for the patient, her family, and her caregivers. In the future, ECLS systems may be used as a bridge to destiny similar to left ventricular assist devices in patients with LV failure. Although fascinating and appealing, these developments will be accompanied by failures, drawbacks, and devastating complications.

SUMMARY AND OUTLOOK
Despite advances in medical therapy, PAH remains a lethal condition for many patients. With disease progression, the marginalized right ventricle is susceptible to failure. Owing to the expertise required to manage these patients, their inherent complexity, and resource requirements, these patients are best managed in experienced centers (10). The principles of care should focus on improving RV function and oxygen delivery to prevent the development of multiorgan failure, by optimizing preload, reducing afterload, and improving RV contractility. Preservation of coronary blood flow and avoiding treatment-induced increases in heart rate should also guide treatment decisions. Unfortunately, there are few data to guide clinicians on the best pharmacological therapies in these patients. There is a clear need to improve our understanding of RV adaptation and develop strategies to avoid RV decompensation (117). At present, most of the data are derived from animal models of pulmonary hypertension. Treatment decisions therefore are based on biological plausibility and clinical experience. Extracorporeal support is currently regarded as a bridge to lung transplantation, but may one day become a destination therapy. Lung transplantation and pulmonary endarterectomy remain definitive destination therapies in select patients who are eligible for these surgical treatments. Patients who are not eligible for destination therapy need to be counseled in advance to ensure that discussions regarding treatment options, end-of-life decision-making, and, when appropriate, palliative measures are instituted.

Author Disclosure: M.M.H. has received consulting fees from Actelion, Bayer, Gilead, GlaxoSmithKline (GSK), Lilly, Pfizer, and Novartis; he has received travel support from Actelion, Bayer, Gilead, GSK, Lilly, and Pfizer; he has received lecture fees from Actelion, Bayer, GSK, Lilly, and Pfizer; J.G. has received consulting fees from GSK and Lilly; he has received expert witness fees from Pfizer; he has received travel support from Actelion; his institution has received grants from Actelion and Pfizer; and his institution has received lecture fees from Actelion; his institution has received lecture fees from Lilly and GSK; his institution has received payment for development of educational presentations from Actelion, Pfizer, GSK, United, and Lilly.

References
For the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2009;30:2493–2537.


25. Handoko ML, Lamberts RR, Redout EM, de Man FS, Boer C, Simonides WS, Paulus WJ, Westerhof N, Allaart CP, Vonk-Noordegraaf A. Right ventricular pacing improves right heart function in...


80. Myles PS, Hall JL, Berry CB, Esmore DS. Primary pulmonary hypertension: prolonged cardiac arrest and successful resuscitation


